Evidence map›Paper›PMID 36620598›Full record

ArticleFrontiers in oncology2022

Association of genetic ancestry with HER2, GRB7 AND estrogen receptor expression among Colombian women with breast cancer.

Laura Rey-Vargas, Lina María Bejarano-Rivera, Juan Carlos Mejia-Henao, Luz F Sua, Jhon Faustino Bastidas-Andrade, Carlos Andrés Ossa, Luz Dary Gutiérrez-Castañeda, Laura Fejerman, María Carolina Sanabria-Salas, Silvia J Serrano-Gómez

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Laura Rey-VargasCancer Biology Research Group, National Cancer Institute of Colombia, Bogotá, Colombia.
Lina María Bejarano-RiveraCancer Biology Research Group, National Cancer Institute of Colombia, Bogotá, Colombia.
Juan Carlos Mejia-HenaoOncological Pathology Research Group, National Cancer Institute of Colombia, Bogotá, Colombia.
Luz F SuaDepartment of Pathology and Laboratory Medicine, Fundación Valle del Lili, and Faculty of Health Sciences, Universidad ICESI, Cali, Colombia.
Jhon Faustino Bastidas-AndradeOncology Unit, Fundación San Pedro Hospital, Pasto, Colombia.
Carlos Andrés OssaCancer Institute, Las Américas Clinic, Medellín, Colombia.
Luz Dary Gutiérrez-CastañedaResearch Institute, Group of Basic Sciences in Health (CBS), Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia.
Laura FejermanDepartment of Public Health Sciences and Comprehensive Cancer Center, University of California Davis, Davis, CA, United States.
María Carolina Sanabria-SalasCancer Biology Research Group, National Cancer Institute of Colombia, Bogotá, Colombia.
Silvia J Serrano-GómezCancer Biology Research Group, National Cancer Institute of Colombia, Bogotá, Colombia.
Instituto Nacional de Cancerología · COFundación Hospital San Pedro · COFundación Universitaria de Ciencias de la Salud · COFundación Valle del Lili · COInstituto de Cancerología Las Américas · COPontificia Universidad Javeriana · COUniversity of California, Davis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Our previous study reported higher mRNA levels of the human epidermal growth factor receptor 2 (HER2)-amplicon genes Methods: We estimated genetic ancestry from non-tumoral breast tissue DNA and assessed tumoral protein expression of ER, HER2, and GRB7 by immunohistochemistry in a cohort of Colombian patients from different health institutions. We used binomial and multinomial logistic regression models to test the association between genetic ancestry and protein expression. Kaplan-Meier and log-rank tests were used to evaluate the effect of HER2/GRB7 co-expression on patients' survival. Results: Our results show that patients with higher IA ancestry have higher odds of having HER2+/GRB7- breast tumors, compared to the HER2-/GRB7- subtype, and this association seems to be stronger among ER-positive tumors (ER+/HER2+/GRB7-: OR=3.04, 95% CI, 1.47-6.37, p<0.05). However, in the multivariate model this association was attenuated (OR=1.80, 95% CI, 0.72-4.44, p=0.19). On the other hand, it was observed that having a higher European ancestry patients presented lower odds of ER+/HER2+/GRB7- breast tumors, this association remained significant in the multivariate model (OR=0.36, 95% CI, 0.13 - 0.93, p= 0.0395). The survival analysis according to HER2/GRB7 co-expression did not show statistically significant differences in the overall survival and recurrence-free survival. Conclusions: Our results suggest that Colombian patients with higher IA ancestry and a lower European fraction have higher odds of ER+/HER2+/GRB7- tumors compared to ER+/HER2-/GRB7- disease. However, this association does not seem to be associated with patients' overall or recurrence-free survival.

Indexed as

American native continental ancestrybreast neoplasmsestrogen receptorGRB7 adaptor proteinreceptor ErbB-2

Identifiers

PMID36620598
PMCPMC9815522
OpenAlexW4312188217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.